News brief­ing: Chi­nese can­cer play­er gets $124M+ Se­ries C; IN8bio sets terms for $86M IPO

A lit­tle less than two years af­ter a nine-fig­ure Se­ries B, Apol­lomics has re­turned to the ven­ture well.

This time, the com­pa­ny has come out with even more mon­ey, pulling in $124.2 mil­lion for a Se­ries C round. The fund­ing will go main­ly to­ward de­vel­op­ing Apol­lomics’ lead pro­grams APL-101 and APL-106.

Ping An Cap­i­tal led the fund­ing, and sev­er­al new and ex­ist­ing in­vestors par­tic­i­pat­ed, though Apol­lomics did not dis­close any oth­er sources. The com­pa­ny was in­cu­bat­ed by Or­biMed Asia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER